Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company specializing in targeted therapeutics for immunology, immuno-oncology, and rare genetic diseases. Their lead product, AVTX-002, is a fully human anti-LIGHT monoclonal antibody undergoing Phase II clinical trials for non-eosinophilic asthma, inflammatory bowel disease, and a Phase III trial for COVID-19 acute respiratory distress syndrome. Additionally, they are developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody for still's disease, and products for rare genetic diseases in Phase III clinical trials, including AVTX-801 for PGM1 deficiency and AVTX-803 for LADII. The company generates revenue through the development and commercialization of these targeted therapeutics.

Products

• AVTX-002 (anti-LIGHT monoclonal antibody)

• AVTX-007 (Anti-IL-18 monoclonal antibody)

• AVTX-801 (PGM1 deficiency treatment)

• AVTX-803 (LADII treatment)